SCHEMBL18458382

SCHEMBL18458382

CC(C)(Br)C(=O)Nc1ccccc1F

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 2/20 0.68
PDK2 Q15119 2/20 0.68
PDK3 Q15120 2/20 0.68
PDK4 Q16654 2/20 0.68
RAB9A P51151 6/20 0.60
NPC1 O15118 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
ALDH1A1 P00352 6/20 0.59
KDM4E B2RXH2 1/20 0.59
ALOX12 P18054 1/20 0.59
HTT P42858 3/20 0.54
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 1/20 0.50
LMNA P02545 2/20 0.49
POLB P06746 1/20 0.49
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089699 0.87 RAB9A (0.71) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL8023112 0.86 CETP (0.53) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL1576313 0.81 PDK1 (0.67) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL6350100 0.81 PDK1 (1.00) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL22472038 0.79 RAB9A (0.62) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL1555152 0.79 GAA (0.54) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL19280535 0.79 PDK1 (0.68) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL6753905 0.79 PDK1 (0.64) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL31381671 0.77 PDK1 (0.53) PDK1PDK2PDK3PDK4RAB9A
SCHEMBL1430533 0.76 RAB9A (0.69) PDK1PDK2PDK3PDK4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428051-B2 Substituted amide derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-10-01 US disclosed
US-10428051-B2 Substituted amide derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-10-01 US disclosed
EP-3328853-B1 SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS SA (ES) 2019-09-11 EP disclosed
EP-3328853-B1 SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS SA (ES) 2019-09-11 EP disclosed
US-20190002443-A1 SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-01-03 US disclosed
US-20190002443-A1 SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-01-03 US disclosed
WO-2017016669-A1 SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428051-B2 Substituted amide derivatives having multimodal activity against pain OPRM1, OPRD1, OPRK1 PDK1 3528/4885PDK2 3774/4885PDK3 3232/4885
US-20190002443-A1 SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRM1, OPRD1, OPRK1 PDK1 3528/4885PDK2 3774/4885PDK3 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.